Breaking News Instant updates and real-time market news.

AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

, RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

12:02
11/21/18
11/21
12:02
11/21/18
12:02

BMO says Aquestive loss on Suboxone appeal disappointing but manageable

BMO Capital analyst Gary Nachman noted that Aquestive Therapeutics (AQST) partner Indivior lost an appeals court ruling regarding the preliminary injunction that previously prevented Dr. Reddy's (RDY) from selling its generic version of Suboxone sublingual film. While he said the decision is disappointing and surprising, and could trigger an at-risk launch by Dr. Reddy's, Nachman sees the situation as fluid and "very manageable." There is certainly a possibility Indivior and Dr. Reddy's could settle, said the analyst, who adds that ex-U.S. Suboxone revenue, while currently small, is a much bigger driver of long-term value. Nachman has an Outperform rating and $26 price target on Aquestive shares.

AQST

Aquestive Therapeutics

$9.71

-3.465 (-26.31%)

RDY

Dr. Reddy's

$36.77

0.29 (0.79%)

  • 29

    Jan

AQST Aquestive Therapeutics
$9.71

-3.465 (-26.31%)

09/12/18
WEDB
09/12/18
INITIATION
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
09/13/18
WEDB
09/13/18
INITIATION
Target $33
WEDB
Outperform
Aquestive Therapeutics initiated with an Outperform at Wedbush
Wedbush analyst Liana Moussatos started coverage of Aquestive Therapeutics with an Outperform rating and $33 price target. The analyst considers Aquestive Therapeutics to be an opportunity to invest in proprietary PharmFilm technology being leveraged to develop a pipeline of 10 drugs and candidates and to provide an oral alternative in patients having difficulty swallowing pills or only having invasive options like injections.
11/19/18
JMPS
11/19/18
NO CHANGE
Target $31
JMPS
Outperform
Aquestive CRL for 'peripheral' program has no read-through, says JMP Securities
After the FDA issued a CRL for Aquestive Therapeutics' tadalafil oral film candidate, JMP Securities analyst Jason Butler said he did not have this "peripheral" product in his valuation for Aquestive shares and he does not believe it is a major focus for investors. The issues raised by FDA appear specific to this product and he does not see any negative read-through to the company's other programs, Butler tells investors. He maintains an Outperform rating and $31 price target on Aquestive shares.
RDY Dr. Reddy's
$36.77

0.29 (0.79%)

03/27/18
EVER
03/27/18
NO CHANGE
Target $155
EVER
Outperform
Evercore sees higher chances of Revlimid patent settlement for Celgene
Evercore ISI analyst Umer Raffat believes the odds of a Revlimid patent settlement between Celgene (CELG) and Dr. Reddy's (RDY) have gone up "considerably" following a recent court filing. The filing, according to the analyst, shows Dr. Reddy's agreed to resolve claims construction issues, which he believes "implies a clear alignment in thought process between both sides." A potential settlement on Revlimid remains the biggest catalyst on Celgene in 2018, and could lead a quick re-rating in the valuation multiple, Raffat tells investors in a research note. He keeps Celgene as his top pick for 2018 with an Outperform rating and $155 price target.
05/29/18
RHCO
05/29/18
NO CHANGE
Target $96
RHCO
Hold
Celgene price target lowered to $96 from $106 at SunTrust
SunTrust analyst Yatin Suneja lowered his price target on Celgene (CELG) to $96 after last week's R&D meeting hosted by the management, which "highlighted" the importance of the multiple myeloma program to the company, its research into the mechanism of iMiD drugs, and its pursuit of anti-B-cell maturation antigen in treatment function. The analyst believes that while the company can sustain its position of leadership in myeloma, he is concerned with the overhang on the stock coming from intellectual property litigation on Revlimid, anticipating the stock to remain rangebound until next week's likely generic Revlimid settlement with Dr. Reddy's (RDY).
11/21/18
RBCM
11/21/18
NO CHANGE
Target $24
RBCM
Outperform
Aquestive selloff on generic Suboxone decision overdone, says RBC Capital
RBC Capital analyst Randall Stanicky attributes the added pressure on Aquestive Therapeutics (AQST) shares to yesterday's decision to lift the preliminary injunction on Dr. Reddy's (RDY) launching a generic version of Suboxone. He notes this will impact the milestones that Aquestive receives from Indivior, with the remaining milestones now unlikely. However, he notes that Suboxone in total comprises about $3 per share in value in his model, which is meaningfully less than the two-day selloff of $7 in the stock, which makes the pullback "meaningfully overdone" in his view. Stanicky has an Outperform rating on Aquestive shares with a $24 price target.

TODAY'S FREE FLY STORIES

AMTD

TD Ameritrade

$50.00

-2.07 (-3.98%)

10:40
03/22/19
03/22
10:40
03/22/19
10:40
Options
TD Ameritrade attracts a put spread as shares extend losses »

TD Ameritrade attracts a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

SO

Southern Company

$52.00

0.45 (0.87%)

10:38
03/22/19
03/22
10:38
03/22/19
10:38
Hot Stocks
Southern Company announces closing of $1.67B in loan guarantees for Vogtle units »

Southern Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:35
03/22/19
03/22
10:35
03/22/19
10:35
General news
reasury Action: yields plumbed lows »

Treasury Action: yields…

DISCB

Discovery Inc.

$31.55

(0.00%)

10:34
03/22/19
03/22
10:34
03/22/19
10:34
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

BMY

Bristol-Myers

$48.65

-0.27 (-0.55%)

, CELG

Celgene

$88.99

-0.63 (-0.70%)

10:33
03/22/19
03/22
10:33
03/22/19
10:33
Hot Stocks
Starboard is not short shares of Celgene, Smith says »

Starboard Value's…

BMY

Bristol-Myers

$48.65

-0.27 (-0.55%)

CELG

Celgene

$88.99

-0.63 (-0.70%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 12

    Apr

  • 12

    Apr

  • 25

    Apr

  • 18

    May

  • 20

    May

  • 28

    May

  • 27

    Jun

  • 03

    Sep

CELG

Celgene

$89.01

-0.61 (-0.68%)

, BMY

Bristol-Myers

$48.61

-0.31 (-0.63%)

10:32
03/22/19
03/22
10:32
03/22/19
10:32
Hot Stocks
Smith says Bristol-Myers bid values Celgene for 10 upcoming blockbusters »

Starboard Value's…

CELG

Celgene

$89.01

-0.61 (-0.68%)

BMY

Bristol-Myers

$48.61

-0.31 (-0.63%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 12

    Apr

  • 12

    Apr

  • 25

    Apr

  • 18

    May

  • 20

    May

  • 28

    May

  • 27

    Jun

  • 03

    Sep

CELG

Celgene

$89.10

-0.52 (-0.58%)

, BMY

Bristol-Myers

$48.66

-0.26 (-0.53%)

10:30
03/22/19
03/22
10:30
03/22/19
10:30
Hot Stocks
Starboard's Smith says Bristol-Myers does not need to do any deal »

Starboard Value's…

CELG

Celgene

$89.10

-0.52 (-0.58%)

BMY

Bristol-Myers

$48.66

-0.26 (-0.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Mar

  • 12

    Apr

  • 12

    Apr

  • 25

    Apr

  • 18

    May

  • 20

    May

  • 28

    May

  • 27

    Jun

  • 03

    Sep

FITB

Fifth Third

$24.88

-0.55 (-2.16%)

10:30
03/22/19
03/22
10:30
03/22/19
10:30
Options
Heavy call volume in Fifth Third Bank »

Heavy call volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Apr

  • 23

    Apr

DISCB

Discovery Inc.

$31.55

(0.00%)

10:29
03/22/19
03/22
10:29
03/22/19
10:29
Hot Stocks
Breaking Hot Stocks news story on Discovery Inc. »

Discovery Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

DHI

D.R. Horton

$40.93

0.4 (0.99%)

10:25
03/22/19
03/22
10:25
03/22/19
10:25
Options
D R Horton call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

10:25
03/22/19
03/22
10:25
03/22/19
10:25
General news
U.S. Data Slate - Week of March 25: »

U.S. Data Slate - Week of…

TRCH

Torchlight Energy Resources

$1.64

0.01 (0.61%)

10:25
03/22/19
03/22
10:25
03/22/19
10:25
Conference/Events
Torchlight Energy Resources to hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

INGN

Inogen

$92.59

-2.15 (-2.27%)

10:25
03/22/19
03/22
10:25
03/22/19
10:25
Conference/Events
Inogen participates in a conference call with JPMorgan »

Medical Supplies &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

  • 10

    Apr

  • 12

    Jun

10:25
03/22/19
03/22
10:25
03/22/19
10:25
Conference/Events
Cowen Washington policy strategist to hold an analyst/industry conference call »

Washington Strategist…

LOV

Spark Networks

$12.78

1.49 (13.20%)

10:25
03/22/19
03/22
10:25
03/22/19
10:25
Conference/Events
Spark Networks to host conference call »

Conference call to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Mar

UTX

United Technologies

$125.73

-1.16 (-0.91%)

10:23
03/22/19
03/22
10:23
03/22/19
10:23
Hot Stocks
NORESCO announces $86.8M ESPC to enhance energy security for Navy Region Japan »

NORESCO is implementing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:20
03/22/19
03/22
10:20
03/22/19
10:20
General news
FX Action: The dollar »

FX Action: The dollar was…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

10:17
03/22/19
03/22
10:17
03/22/19
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

10:16
03/22/19
03/22
10:16
03/22/19
10:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:15
03/22/19
03/22
10:15
03/22/19
10:15
General news
U.S. wholesale inventories rose 1.2% in January, with sales up 0.5% »

U.S. wholesale…

10:15
03/22/19
03/22
10:15
03/22/19
10:15
General news
U.S. existing home sales surged 11.8% to 5.510 M in February »

U.S. existing home sales…

BITCOIN

Bitcoin

$0.00

(0.00%)

, BTC

Bitcoin

$0.00

(0.00%)

10:14
03/22/19
03/22
10:14
03/22/19
10:14
On The Fly
The Intersection: Crypto and Wall Street This Week »

As bitcoin, ethereum and…

BITCOIN

Bitcoin

$0.00

(0.00%)

BTC

Bitcoin

$0.00

(0.00%)

SQ

Square

$76.69

-1.89 (-2.41%)

TWTR

Twitter

$33.68

1.07 (3.28%)

ICE

IntercontinentalExchange

$72.54

-0.82 (-1.12%)

CBOE

Cboe Global Markets

$93.64

-1.14 (-1.20%)

IBM

IBM

$140.22

-1.15 (-0.81%)

BBD

Banco Bradesco

$10.66

-0.56 (-4.99%)

OSTK

Overstock.com

$19.17

-0.32 (-1.64%)

AMD

AMD

$26.94

-0.96 (-3.44%)

NVDA

Nvidia

$181.03

-2.89 (-1.57%)

DPW

DPW Holdings

$0.63

0.0299 (4.98%)

KODK

Kodak

$3.05

-0.125 (-3.94%)

IDEX

Ideanomics

$1.82

0.03 (1.68%)

RIOT

Riot Blockchain

$3.57

-0.1 (-2.72%)

TEUM

Pareteum

$4.57

-0.13 (-2.77%)

SRAX

Social Reality

$2.50

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 01

    Apr

  • 04

    Apr

  • 23

    Apr

  • 30

    Apr

  • 02

    May

  • 17

    May

  • 28

    May

  • 28

    May

TWTR

Twitter

$33.97

1.36 (4.17%)

10:10
03/22/19
03/22
10:10
03/22/19
10:10
Options
Active trading in Twitter as shares see relative strength »

Active trading in Twitter…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Mar

  • 04

    Apr

  • 23

    Apr

10:10
03/22/19
03/22
10:10
03/22/19
10:10
General news
Treasury Action: the 3-month-10-year spread has dropped on zero »

Treasury Action: the…

NKE

Nike

$84.09

-3.96 (-4.50%)

, FL

Foot Locker

$58.72

-1.05 (-1.76%)

10:08
03/22/19
03/22
10:08
03/22/19
10:08
On The Fly
Nike drops after sales growth in North America disappoints »

Shares of Nike (NKE)…

NKE

Nike

$84.09

-3.96 (-4.50%)

FL

Foot Locker

$58.72

-1.05 (-1.76%)

UA

Under Armour

$19.00

-0.28 (-1.45%)

UAA

Under Armour

$21.37

-0.32 (-1.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Mar

  • 28

    Mar

  • 04

    Apr

  • 04

    Apr

  • 24

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.